National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Clinical Trials (PDQ®)
Patient VersionHealth Professional Version
Last Modified: 11/6/2009     First Published: 3/24/2004  
Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

Quick Links
Help Using the NCI Clinical Trials Search Form

Educational Materials About Clinical Trials

About NCI's Cancer Clinical Trials Registry

Dictionary of Cancer Terms

NCI Drug Dictionary
Phase III Randomized Study of Single Fraction Versus Multiple Fraction Re-Irradiation in Patients With Painful Bone Metastases

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Related Publications
Trial Contact Information
Registry Information

Alternate Title

Single-Fraction Radiation Therapy Compared With Multiple-Fraction Reirradiation Therapy in Treating Patients With Painful Bone Metastases

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentActive18 and overNCI, OtherCAN-NCIC-SC20
NCT00080912, RTOG-0433, TROG 03.08, SC20

Objectives

Primary

  1. Compare pain relief in patients undergoing single-fraction vs multiple-fraction re-irradiation of painful bone metastases.

Secondary

  1. Compare overall pain relief in patients treated with these regimens.
  2. Compare time to pain progression in patients treated with these regimens.
  3. Correlate initial irradiation response with pain relief after re-irradiation in these patients.
  4. Compare changes in functional interference after re-irradiation using the Brief Pain Inventory in patients treated with these regimens.
  5. Compare quality of life of patients treated with these regimens (patients in Canada, the Netherlands, and patients registered through RTOG).
  6. Determine characteristics of non-responders (to both initial and re-irradiation) among patients treated with these regimens.
  7. Monitor the incidence of acute severe radiation-related side effects in patients treated with these regimens.
  8. Monitor the incidence of in-field pathological fractures and spinal cord compression in patients treated with these regimens.

Entry Criteria

Disease Characteristics:

  • Histologically or cytologically confirmed malignancy
    • Diagnosis by needle biopsy, bone marrow biopsy, cytology, or surgical biopsy or resection
  • Bone metastases at clinically painful areas confirmed by any of the following:
    • Plain radiographs
    • Radionuclide bone scans
    • CT scans
    • Magnetic resonance imaging
  • Worst pain score of ≥ 2/10 using the baseline Brief Pain Inventory
  • Pain arising from previously irradiated metastases and not from progressive disease in adjoining or remote areas
  • Initial radiotherapy field is reproducible for re-irradiation
    • Current treatment field for palliative radiotherapy must be the same size or smaller than the initial treatment field
  • No radiological evidence of high-risk lesions for pathological fractures in the extremities (lytic lesions > 3cm or > 50% cortical erosion of bone diameter) AND patient is a candidate for surgical intervention.
  • No clinical or radiological evidence of spinal cord compression

Prior/Concurrent Therapy:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • See Disease Characteristics
  • No more than 1 prior course of radiotherapy to the target site
  • No prior radiotherapy dose ≥ 24 Gy in 6 fractions, 27 Gy in 8 fractions, or 30 Gy in 10 fractions to the spine or any part of the pelvis encompassing small or large bowel and/or the rectum, if these sites are being treated on study
    • Initial doses of 24 Gy in 6 fractions, 27 Gy in 8 fractions or 30 Gy in 10 fractions to the acetabulum or hip and proximal femur allowed as long as the medial field border of the initial treatment did not cross midline
  • No prior radiotherapy dose > 30Gy in 10 fractions to the ribs or extremities if these sites are being treated on study
  • More than 30 days since prior strontium chloride Sr 89
  • More than 30 days since prior half-body radiotherapy, including the current re-irradiation field
  • At least 4 weeks since prior initial radiotherapy

Surgery

  • No prior palliative surgery in treatment area
  • No concurrent surgical intervention on treatment area

Other

  • No prior participation on this protocol
  • No plan to make an immediate change in analgesic regimen

Patient Characteristics:

Age

  • 18 and over

Performance status

  • Karnofsky 50-100%

Life expectancy

  • Not specified

Hematopoietic

  • Not specified

Hepatic

  • Not specified

Renal

  • Not specified

Other

  • Not pregnant or nursing
  • Fertile patients must use effective barrier contraception
  • Able and willing to complete quality of life questionnaire in English, French, Dutch, or Spanish
  • Must be accessible for treatment follow-up

Expected Enrollment

850

A total of 650 patients (325 per treatment arm) will be accrued for this study.

Outcomes

Primary Outcome(s)

Pain relief measured by the Brief Pain Inventory at 2 months after treatment

Secondary Outcome(s)

Quality of life assessed by the EORTC QLQ-C30

Outline

This is a randomized, multicenter study. Patients are stratified according to response to initial radiotherapy (yes vs no), initial fractionation (single fraction vs multiple fraction), and participating center. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive single-fraction radiotherapy on day 1.
  • Arm II: Patients receive multiple-fraction radiotherapy once daily on days 1-5 or on days 1-8 if re-irradiation of the spine and/or whole pelvis is involved AND prior initial radiotherapy was given in multiple fractions.

At least 4 weeks after the first re-treatment, patients in both arms may receive a second re-treatment in the absence of unacceptable pain progression or unacceptable toxicity.

Patients complete a Brief Pain Inventory questionnaire at baseline, on days 7 and 14, monthly during months 1-6, and at months 9 and 12. Acute Toxicities are assessed on days 7 and 14. Quality of life is assessed at baseline and then monthly during months 1-6.

Patients are followed for up to 1 year.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

Related Publications

Chow E, Hoskin PJ, Wu J, et al.: A phase III international randomised trial comparing single with multiple fractions for re-irradiation of painful bone metastases: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) SC 20. Clin Oncol (R Coll Radiol) 18 (2): 125-8, 2006.[PUBMED Abstract]

Trial Contact Information

Trial Lead Organizations

NCIC-Clinical Trials Group

Edward Chow, MD, Protocol chair
Ph: 416-480-4998

Radiation Therapy Oncology Group

William Hartsell, MD, Protocol chair
Ph: 847-981-5760

Trial Sites

U.S.A.
California
  Burbank
 Providence Saint Joseph Medical Center - Burbank
 Clinical Trials Office - Providence Saint Joseph Medical Center - Burbank
Ph: 818-847-3220
  Castro Valley
 East Bay Radiation Oncology Center
 James Feusner, MD
Ph: 510-428-3689
 Eden Medical Center
 James Feusner, MD
Ph: 510-428-3689
 Valley Medical Oncology Consultants - Castro Valley
 James Feusner, MD
Ph: 510-428-3689
  Chico
 Enloe Cancer Center at Enloe Medical Center
 Clinical Trials Office - Enloe Cancer Center at Enloe Medical Center
Ph: 530-332-3808
  Fremont
 Kaiser Permanente - Fremont
 Louis Fehrenbacher, MD
Ph: 707-651-2577
 Valley Medical Oncology
 James Feusner, MD
Ph: 510-428-3689
  Hayward
 Kaiser Permanente Medical Center - Hayward
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Los Angeles
 Kaiser Permanente Medical Center - Los Angeles
 Michael Girvigian
Ph: 323-667-4011
800-954-8000
  Martinez
 Contra Costa Regional Medical Center
 James Feusner, MD
Ph: 510-428-3689
  Mountain View
 El Camino Hospital Cancer Center
 Clinical Trials Office - El Camino Hospital Cancer Center
Ph: 650-988-7623
  Oakland
 Alta Bates Summit Medical Center - Summit Campus
 Clinical Trials Office - Alta Bates Summit Medical Center - Summit Campus
Ph: 510-204-1414
 Bay Area Breast Surgeons, Incorporated
 James Feusner, MD
Ph: 510-428-3689
 CCOP - Bay Area Tumor Institute
 James Feusner, MD
Ph: 510-428-3689
 Highland General Hospital
 James Feusner, MD
Ph: 510-428-3689
 Kaiser Permanente - Division of Research - Oakland
 Louis Fehrenbacher, MD
Ph: 707-651-2577
 Kaiser Permanente Medical Center - Oakland
 Louis Fehrenbacher, MD
Ph: 707-651-2577
 Larry G Strieff MD Medical Corporation
 James Feusner, MD
Ph: 510-428-3689
 Tom K Lee, Incorporated
 James Feusner, MD
Ph: 510-428-3689
  Pleasanton
 Valley Care Medical Center
 James Feusner, MD
Ph: 510-428-3689
 Valley Medical Oncology Consultants - Pleasanton
 James Feusner, MD
Ph: 510-428-3689
  Pomona
 Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center
 Clinical Trials Office - Robert and Beverly Lewis Family Cancer Care Center
Ph: 909-865-9555
  Rancho Cardova
 Kaiser Permanente Medical Center - Rancho Cordova
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Redwood City
 Kaiser Permanente Medical Center - Redwood City
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Richmond
 Kaiser Permanente Medical Center - Richmond
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Rohnert Park
 Rohnert Park Cancer Center
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Roseville
 Kaiser Permanente Medical Center - Roseville
 Louis Fehrenbacher, MD
Ph: 707-651-2577
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Sacramento
 Kaiser Permanente Medical Center - Sacramento
 Louis Fehrenbacher, MD
Ph: 707-651-2577
 South Sacramento Cancer Center
 Louis Fehrenbacher, MD
Ph: 707-651-2577
 South Sacramento Kaiser-Permanente Medical Center
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  San Francisco
 Kaiser Permanente Medical Center - San Francisco Geary Campus
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  San Jose
 Kaiser Permanente Medical Center - Santa Teresa
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  San Pablo
 Doctors Medical Center - San Pablo Campus
 James Feusner, MD
Ph: 510-428-3689
  San Rafael
 Kaiser Foundation Hospital - San Rafael
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Santa Clara
 Louis Fehrenbacher, MD
Ph: 707-651-2577
 Kaiser Permanente Medical Center - Santa Clara Kiely Campus
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Santa Rosa
 Kaiser Permanente Medical Center - Santa Rosa
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  South San Francisco
 Kaiser Permanente Medical Center - South San Francisco
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Stockton
 Kaiser Permanente Medical Facility - Stockton
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Vallejo
 Kaiser Permanente Medical Center - Vallejo
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Walnut Creek
 Kaiser Permanente Medical Center - Walnut Creek
 Louis Fehrenbacher, MD
Ph: 707-651-2577
Colorado
  Aurora
 University of Colorado Cancer Center at UC Health Sciences Center
 Clinical Trials Office - University of Colorado Cancer Center
Ph: 720-848-0650
  Colorado Springs
 Penrose Cancer Center at Penrose Hospital
 Clinical Trials Office - Penrose Cancer Center
Ph: 719-776-5275
  Fort Collins
 Poudre Valley Radiation Oncology
 C. Kelley Simpson, MD
Ph: 970-482-3328
  Pueblo
 St. Mary - Corwin Regional Medical Center
 John Stageberg
Ph: 719-557-4000
Florida
  Miami
 University of Miami Sylvester Comprehensive Cancer Center - Miami
 University of Miami Sylvester Comprehensive Cancer Center Clinical Trial Matching Service
Ph: 866-574-5124
 Email: Sylvester@emergingmed.com
Georgia
  Altanta
 Winship Cancer Institute of Emory University
 Scott Edelman
Ph: 404-778-5180
888-946-7447
  Atlanta
 Emory Crawford Long Hospital
 Scott Edelman
Ph: 404-686-4411
 Georgia Cancer Center for Excellence at Grady Memorial Hospital
 Scott Edelman
Ph: 404-489-9000
  Decatur
 Veterans Affairs Medical Center - Atlanta (Decatur)
 Scott Edelman
Ph: 404-728-7680
  Gainesville
 Northeast Georgia Medical Center
 Frank Lake, MD
Ph: 770-535-3393
Illinois
  Barrington
 Good Shepherd Hospital
 John Chang, MD
Ph: 847-723-8030
  Chicago
 Creticos Cancer Center at Advocate Illinois Masonic Medical Center
 Clinical Trials Office - Creticos Cancer Center at Advocate Illinois Masonic Medical Center
Ph: 773-296-5360
 John H. Stroger, Jr. Hospital of Cook County
 Nathanial Holloway
Ph: 312-864-3200
  Downers Grove
 Good Samaritan Cancer Care Center at Advocate Good Samaritan Hospital
 Clinical Trials Office - Good Samaritan Cancer Care Center at Advocate Good Samaritan Hospital
Ph: 630-275-1270
  Elk Grove Village
 Alexian Brothers Radiation Oncology
 Martin Boyer, MD
Ph: 847-981-5760
  Park Ridge
 Advocate Lutheran General Cancer Care Center
 Clinical Trials Office - Advocate Lutheran General Cancer Care Center
Ph: 847-384-3621
  Peoria
 Methodist Medical Center of Illinois
 Clinical Trials Office - Methodist Medical Center of Illinois
Ph: 309-243-3000
Indiana
  Elkhart
 Elkhart General Hospital
 David Hornback, MD
Ph: 574-647-7461
  Fort Wayne
 Parkview Regional Cancer Center at Parkview Health
 Brian Chang
Ph: 260-373-7850
 Radiation Oncology Associates Southwest
 Tony Lee
Ph: 260-373-7850
  Indianapolis
 Indiana University Melvin and Bren Simon Cancer Center
 Clinical Trials Office - Indiana University Cancer Center
Ph: 317-274-2552
 Veterans Affairs Medical Center - Indianapolis
 Achilles Fakiris
Ph: 317-554-0000
888-878-6889
  Kokomo
 Howard Community Hospital
 David Hornback, MD
Ph: 574-647-7461
  La Porte
 Center for Cancer Therapy at LaPorte Hospital and Health Services
 David Hornback, MD
Ph: 574-647-7461
  South Bend
 CCOP - Northern Indiana CR Consortium
 David Hornback, MD
Ph: 574-647-7461
 Memorial Hospital of South Bend
 Clinical Trials Office - Memorial Hospital of South Bend
Ph: 800-284-7370
 Saint Joseph Regional Medical Center
 David Hornback, MD
Ph: 574-647-7461
 South Bend Clinic
 David Hornback, MD
Ph: 574-647-7461
Kansas
  Overland Park
 Menorah Medical Center
 Rakesh Gaur, MD
Ph: 816-823-0555
 Saint Luke's Hospital - South
 Rakesh Gaur, MD
Ph: 816-823-0555
  Shawnee Mission
 Shawnee Mission Medical Center
 Rakesh Gaur, MD
Ph: 816-823-0555
Kentucky
  Lexington
 Lucille P. Markey Cancer Center at University of Kentucky
 Clinical Trials Office - Markey Cancer Center at University of Kentucky Chandler Medical Center
Ph: 859-257-3379
Massachusetts
  Boston
 Boston University Cancer Research Center
 Clinical Trials Office - Boston University Cancer Research Center
Ph: 617-353-7571
Michigan
  Adrian
 Hickman Cancer Center at Bixby Medical Center
 Clinical Trials Office - Hickman Cancer Center at Bixby Medical Center
Ph: 517-265-0116
  Ann Arbor
 University of Michigan Comprehensive Cancer Center
 Clinical Trials Office - University of Michigan Comprehensive Cancer Center
Ph: 800-865-1125
  Escanaba
 Green Bay Oncology, Limited - Escanaba
 Gregory Cooley, MD
Ph: 414-433-8184
  Iron Mountain
 Dickinson County Healthcare System
 Gregory Cooley, MD
Ph: 414-433-8184
  Kalamazoo
 Borgess Medical Center
 Raymond Lord, MD
Ph: 269-373-7458
 Bronson Methodist Hospital
 Raymond Lord, MD
Ph: 269-373-7458
 West Michigan Cancer Center
 Clinical Trials Office - West Michigan Cancer Center
Ph: 269-373-7458
  Lambertville
 Haematology-Oncology Associates of Ohio and Michigan, PC
 Paul Schaefer, MD
Ph: 419-479-5605
  Monroe
 Community Cancer Center of Monroe
 Paul Schaefer, MD
Ph: 419-479-5605
 Mercy Memorial Hospital - Monroe
 Paul Schaefer, MD
Ph: 419-479-5605
  St. Joseph
 Lakeland Regional Cancer Care Center - St. Joseph
 David Hornback, MD
Ph: 574-647-7461
Minnesota
  Saint Cloud
 CentraCare Clinic - River Campus
 Barbi Kaplan-Frenkel, DO
Ph: 320-229-4901
 Coborn Cancer Center
 Barbi Kaplan-Frenkel, DO
Ph: 320-229-4901
Missouri
  Kansas City
 CCOP - Kansas City
 Rakesh Gaur, MD
Ph: 816-823-0555
 North Kansas City Hospital
 Rakesh Gaur, MD
Ph: 816-823-0555
 Parvin Radiation Oncology
 Rakesh Gaur, MD
Ph: 816-823-0555
 Research Medical Center
 Rakesh Gaur, MD
Ph: 816-823-0555
 Saint Luke's Cancer Institute at Saint Luke's Hospital
 Rakesh Gaur, MD
Ph: 816-823-0555
 St. Joseph Medical Center
 Rakesh Gaur, MD
Ph: 816-823-0555
 Truman Medical Center - Hospital Hill
 Rakesh Gaur, MD
Ph: 816-823-0555
  Lee's Summit
 Saint Luke's East - Lee's Summit
 Rakesh Gaur, MD
Ph: 816-823-0555
  Liberty
 Liberty Hospital
 Rakesh Gaur, MD
Ph: 816-823-0555
  Saint Joseph
 Heartland Regional Medical Center
 Rakesh Gaur, MD
Ph: 816-823-0555
Nebraska
  Kearney
 Good Samaritan Cancer Center at Good Samaritan Hospital
 Clinical Trials Office - Good Samaritan Cancer Center at Good Samaritan Hospital
Ph: 308-865-7963
  Omaha
 Methodist Estabrook Cancer Center
 Tien-Shew Huang
Ph: 402-354-5890
877-850-3212
New Hampshire
  Keene
 Kingsbury Center for Cancer Care at Cheshire Medical Center
 Alan Hartford, MD, PhD
Ph: 603-650-6600
  Lebanon
 Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
 Clinical Trials Office - Norris Cotton Cancer Center
Ph: 603-650-7609
 Email: cancerhelp@dartmouth.edu
New Jersey
  Camden
 Cancer Institute of New Jersey at Cooper University Hospital - Camden
 Clinical Trial Office - Cancer Institute of New Jersey at Cooper Uniersity Hospital
Ph: 856-325-6757
  Voorhees
 Cancer Institute of New Jersey at Cooper - Voorhees
 Clinical Trials Office - Cancer Institute of New Jersey at Cooper University Hospital - Voorhees
Ph: 856-325-6757
New York
  Brooklyn
 Veterans Affairs Medical Center - Brooklyn
 Contact Person
Ph: 718-630-3574
  East Syracuse
 CCOP - Hematology-Oncology Associates of Central New York
 Jeffrey Kirshner, MD
Ph: 315-472-7504
North Carolina
  Goldsboro
 Wayne Memorial Hospital, Incorporated
 James Atkins, MD
Ph: 919-580-0000
 Wayne Radiation Oncology
 James Atkins, MD
Ph: 919-580-0000
  Rutherfordton
 Rutherford Hospital
 James Bearden, MD
Ph: 864-560-6812
Ohio
  Akron
 Summa Center for Cancer Care at Akron City Hospital
 Clinical Trials Office - Akron City Hospital
Ph: 330-375-6101
  Barberton
 Barberton Citizens Hospital
 William Demas, MD
Ph: 330-375-3557
  Bowling Green
 Wood County Oncology Center
 Paul Schaefer, MD
Ph: 419-479-5605
  Cleveland
 Cleveland Clinic Cancer Center at Fairview Hospital
 Clinical Trials Office - Cleveland Clinic Cancer Center at Fairview Hospital
Ph: 216-476-9362
 Cleveland Clinic Taussig Cancer Center
 Clinical Trials Office - Cleveland Clinic Taussig Cancer Center
Ph: 866-223-8100
  Clyde
 North Coast Cancer Care - Clyde
 Paul Schaefer, MD
Ph: 419-479-5605
  Dayton
 David L. Rike Cancer Center at Miami Valley Hospital
 Clinical Trials Office - David L. Rike Cancer Center at Miami Valley Hospital
Ph: 937-208-2079
  Elyria
 Hematology Oncology Center
 Paul Schaefer, MD
Ph: 419-479-5605
  Independence
 Cleveland Clinic Cancer Center
 John Suh, MD
Ph: 216-444-5574
  Lima
 Lima Memorial Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
  Maumee
 Northwest Ohio Oncology Center
 Paul Schaefer, MD
Ph: 419-479-5605
 Paul Schaefer, MD
Ph: 419-479-5605
 St. Luke's Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
  Mayfield Heights
 Hillcrest Cancer Center at Hillcrest Hospital
 John Suh, MD
Ph: 216-444-5574
  Oregon
 St. Charles Mercy Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
 Toledo Clinic - Oregon
 Paul Schaefer, MD
Ph: 419-479-5605
  Salem
 Cancer Care Center, Incorporated
 William Demas, MD
Ph: 330-375-3557
  Sandusky
 North Coast Cancer Care, Incorporated
 Paul Schaefer, MD
Ph: 419-479-5605
  Sylvania
 Flower Hospital Cancer Center
 Clinical Trials Office - Flower Hospital Cancer Center
Ph: 419-824-1842
  Tiffin
 Mercy Hospital of Tiffin
 Paul Schaefer, MD
Ph: 419-479-5605
  Toledo
 CCOP - Toledo Community Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
 Medical University of Ohio Cancer Center
 Clinical Trials Office - Medical University of Ohio Cancer Center
Ph: 419-383-6583
 St. Anne Mercy Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
 St. Vincent Mercy Medical Center
 Paul Schaefer, MD
Ph: 419-479-5605
 Toledo Clinic, Incorporated - Main Clinic
 Paul Schaefer, MD
Ph: 419-479-5605
 Toledo Hospital
 Clinical Trials Office - Toledo Hospital
Ph: 419-824-1842
  Wauseon
 Fulton County Health Center
 Clinical Trials Office - Fulton County Health Center
Ph: 419-330-2708
  Wooster
 Cancer Treatment Center
 Clinical Trials Office - Cancer Treatment Center
Ph: 330-375-4221
 Cleveland Clinic - Wooster
 Clinical Trials Office - Cleveland Clinic - Wooster
Ph: 800-862-7798
Pennsylvania
  Abington
 Rosenfeld Cancer Center at Abington Memorial Hospital
 Clinical Trials Office - Rosenfeld Cancer Center at Abington Memorial Hospital
Ph: 215-481-2402
South Carolina
  Anderson
 AnMed Cancer Center
 Clinical Trials Office - AnMed Cancer Center
Ph: 864-512-1000
  Spartanburg
 CCOP - Upstate Carolina
 Clinical Trials Office - CCOP - Upstate Carolina
Ph: 800-486-5941
 Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
 Clinical Trials Office - Gibbs Regional Cancer Center
Ph: 800-486-5941
Vermont
  Rutland
 Community Cancer Center at Rutland Regional Medical Center
 Richard Lovett, MD
Ph: 802-747-1831
  Saint Johnsbury
 Norris Cotton Cancer Center - North
 Alan Hartford, MD, PhD
Ph: 603-650-6600
Virginia
  Fredericksburg
 Fredericksburg Oncology, Incorporated
 Paul Schaefer, MD
Ph: 419-479-5605
Wisconsin
  Green Bay
 Green Bay Oncology, Limited at St. Mary's Hospital
 Gregory Cooley, MD
Ph: 414-433-8184
 Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
 Gregory Cooley, MD
Ph: 414-433-8184
 St. Mary's Hospital Medical Center - Green Bay
 Gregory Cooley, MD
Ph: 414-433-8184
 St. Vincent Hospital Regional Cancer Center
 Clinical Trials Office - St. Vincent Hospital Regional Cancer Center
Ph: 920-433-8889
  La Crosse
 Gundersen Lutheran Center for Cancer and Blood
 Clinical Trials Office - Gundersen Lutheran Cancer Center
Ph: 608-775-2385
 Email: cancerctr@gundluth.org
  Marinette
 Bay Area Cancer Care Center at Bay Area Medical Center
 Gregory Cooley, MD
Ph: 414-433-8184
  Milwaukee
 Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
 Clinical Trials Office - Vince Lombardi Cancer Clinic
Ph: 414-649-5717
  Oconto Falls
 Green Bay Oncology, Limited - Oconto Falls
 Gregory Cooley, MD
Ph: 414-433-8184
  Sturgeon Bay
 Green Bay Oncology, Limited - Sturgeon Bay
 Gregory Cooley, MD
Ph: 414-433-8184
  West Allis
 West Allis Memorial Hospital
 Clinical Trials Office - West Allis Memorial Hospital
Ph: 414-649-5717
Canada
Alberta
  Calgary
 Tom Baker Cancer Centre - Calgary
 Marc Kerba
Ph: 403-521-3164
New Brunswick
  Moncton
 Doctor Leon Richard Oncology Centre
 Fernando Rojas
Ph: 506-862-4030
Newfoundland and Labrador
  St. John's
 Doctor H. Bliss Murphy Cancer Centre
 Jonathan Greenland
Ph: 709-777-7802
Ontario
  Hamilton
 Margaret and Charles Juravinski Cancer Centre
 William G. McMillan
Ph: 905-387-9495
  Kingston
 Cancer Centre of Southeastern Ontario at Kingston General Hospital
 Catherine de Metz
Ph: 613-549-6666
  Kitchener
 Grand River Regional Cancer Centre at Grand River Hospital
 Dilip Panjwani
Ph: 519-749-4300
  Ottawa
 Ottawa Hospital Regional Cancer Centre - General Campus
 Peter Cross
Ph: 613-737-7700
  Thunder Bay
 Cancer Care Program at Thunder Bay Regional Health Sciences
 Margaret L. Anthes
Ph: 807-684-7211
  Toronto
 Edmond Odette Cancer Centre at Sunnybrook
 Edward L.W. Chow
Ph: 416-480-4998
 Princess Margaret Hospital
 Andrea Bezjak
Ph: 416-946-2132
  Windsor
 Windsor Regional Cancer Centre at Windsor Regional Hospital
 Khalid J. Hirmiz
Ph: 519-253-5253
Quebec
  Montreal
 Hopital Notre-Dame du CHUM
 Isabelle Roy
Ph: 514-890-5420
 McGill Cancer Centre at McGill University
 Marc David
Ph: 514-934-8040
  Sherbrooke
 CHUS-Hopital Fleurimont
 Abdenour Nabid
Ph: 819-346-1110

Registry Information
Official Title A Phase III International Randomized Trial Of Single Versus Multiple Fractions For Re-Irradiation Of Painful Bone Metastases
Trial Start Date 2004-01-07
Trial Completion Date 2010-12-31 (estimated)
Registered in ClinicalTrials.gov NCT00080912
Date Submitted to PDQ 2004-02-17
Information Last Verified 2009-11-06

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.

Back to TopBack to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov